Ascletis Pharma Management

Management criteria checks 2/4

Ascletis Pharma's CEO is Jinzi Jason Wu, appointed in Apr 2013, has a tenure of 10.17 years. total yearly compensation is CN¥22.58M, comprised of 99.5% salary and 0.5% bonuses, including company stock and options. directly owns 50.91% of the company’s shares, worth €82.50M. The average tenure of the management team and the board of directors is 3.1 years and 6 years respectively.

Key information

Jinzi Jason Wu

Chief executive officer

CN¥22.6m

Total compensation

CEO salary percentage	99.5%
CEO tenure	11yrs
CEO ownership	50.9%
Management average tenure	3.1yrs
Board average tenure	6yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Jinzi Jason Wu's remuneration changed compared to Ascletis Pharma's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	n/a	n/a	-CN¥145m
Sep 30 2023	n/a	n/a	-CN¥194m
Jun 30 2023	n/a	n/a	-CN¥243m
Mar 31 2023	n/a	n/a	-CN¥279m
Dec 31 2022	CN¥23m	CN¥22m	-CN¥315m
Sep 30 2022	n/a	n/a	-CN¥246m
Jun 30 2022	n/a	n/a	-CN¥176m
Mar 31 2022	n/a	n/a	-CN¥188m
Dec 31 2021	CN¥20m	CN¥20m	-CN¥199m
Sep 30 2021	n/a	n/a	-CN¥234m
Jun 30 2021	n/a	n/a	-CN¥269m
Mar 31 2021	n/a	n/a	-CN¥239m
Dec 31 2020	CN¥11m	CN¥11m	-CN¥209m
Sep 30 2020	n/a	n/a	-CN¥155m
Jun 30 2020	n/a	n/a	-CN¥100m
Mar 31 2020	n/a	n/a	-CN¥98m
Dec 31 2019	CN¥11m	CN¥11m	-CN¥96m

Compensation vs Market: Jinzi Jason's total compensation ($USD3.12M) is above average for companies of similar size in the German market ($USD678.96K).

Compensation vs Earnings: Jinzi Jason's compensation has increased whilst the company is unprofitable.

CEO

Jinzi Jason Wu (59 yo)

11yrs

Tenure

CN¥22,584,000

Compensation

Dr. Jinzi Jason Wu Ph D, is a Founder of Ascletis Pharma Inc and has been its Chairman March 30, 2018 and has been its CEO since April 2013. In 2013, Dr. Wu founded Ascletis BioScience Co., Ltd.a pharmace...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Jinzi Jason Wu	Founder	11yrs	CN¥22.58m	50.91% CN¥ 82.5m
Hejingdao Wu	Senior VP of Operations & Executive Director	3.1yrs	CN¥2.67m	0.11% CN¥ 184.9k
Yuemei Yan	Senior Vice President of Clinical Development Operations	3.1yrs	no data	no data
Kristjan Gudmundsson	Senior Consultant & Head of Discovery	10.9yrs	no data	no data
George Hill	Senior Consultant & Chief Medical Advisor	6.6yrs	no data	no data
John Gargiulo	Chief Business Officer	1.8yrs	no data	no data
Ming Fai Chung	Company Secretary	1.7yrs	no data	no data

3.1yrs

Average Tenure

54yo

Average Age

Experienced Management: 2VJ's management team is considered experienced (3.1 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Jinzi Jason Wu	Founder	10.2yrs	CN¥22.58m	50.91% CN¥ 82.5m
Hejingdao Wu	Senior VP of Operations & Executive Director	6.1yrs	CN¥2.67m	0.11% CN¥ 184.9k
Jiong Gu	Independent Non-Executive Director	6yrs	CN¥384.00k	no data
Yizhen Wei	Independent Non-Executive Director	6yrs	CN¥383.00k	no data
Lin Hua	Independent Non-Executive Director	6yrs	CN¥383.00k	no data

6.0yrs

Average Tenure

49yo

Average Age

Experienced Board: 2VJ's board of directors are considered experienced (6 years average tenure).

Ascletis Pharma Management

Management criteria checks 2/4

Key information

Recent management updates

Insufficient new directors

Insufficient new directors

Insufficient new directors

Ascletis Pharma Inc., Annual General Meeting, Jun 29, 2023

Insufficient new directors

Ascletis Pharma Inc. Announces Change of Company Secretary

Recent updates

Ascletis Pharma Inc. Announces Strategic Decisions on FXR Agonist ASC42

Full year 2023 earnings released: CN¥0.14 loss per share (vs CN¥0.29 loss in FY 2022)

Ascletis Pharma Inc. Announces Poster Presentation of Phase II Study Final Results of FASN Inhibitor ASC40 for Treatment of Acne at 2024 AAD Annual Meeting

Ascletis Pharma Inc. to Report Fiscal Year 2023 Results on Mar 25, 2024

Ascletis Pharma Inc. Announces Dosing of the First Patient in Phase III Clinical Trial of Asc40 (Denifanstat) for Treatment of Acne

Insufficient new directors

New major risk - Revenue and earnings growth

Ascletis Pharma Inc. Announces Positive Interim Results from 52-Week Phase Ii Clinical Trial of Once-Daily Asc41 Tablet in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis

Insufficient new directors

Ascletis Pharma Inc. Announces Initiation of Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of Acne

First half 2023 earnings released: CN¥0.015 loss per share (vs CN¥0.081 loss in 1H 2022)

Ascletis Pharma Inc. Announces Positive Interim Data from the Phase IIb Expansion Cohort of ASC22 (Envafolimab) for Chronic Hepatitis B Functional Cure

Ascletis Pharma Inc. Announces Completion of Enrollment of 120 Patients in the Phase Ii Clinical Trial of FASN Inhibitor ASC40 Combined with Bevacizumab for Treatment of Recurrent Glioblastoma

Insufficient new directors

First half 2023 earnings released: CN¥0.015 loss per share (vs CN¥0.081 loss in 1H 2022)

Ascletis Pharma Inc. to Report Q2, 2023 Results on Aug 21, 2023

Ascletis Pharma Inc. Announces Completion of Patient Enrollment for Phase Ii Clinical Trial of Asc42, an Fxr Agonist, for Primary Biliary Cholangitis

New minor risk - Profitability

Ascletis Pharma Inc., Annual General Meeting, Jun 29, 2023

Ascletis Pharma Inc. Announces China NMPA Approval of Conducting a Phase IIa Clinical Trial for ASC10 to Treat Respiratory Syncytial Virus Infection

Forecast breakeven date moved forward to 2023

Ascletis Pharma Inc. Announces Oral Presentation at APASL Annual Meeting 2023 Demonstrates ASC22, a Subcutaneous PD-L1 Antibody, Can Achieve Functional Cure of Chronic Hepatitis B

Forecast breakeven date moved forward to 2023

Ascletis Pharma Announces U.S. FDA Approval of Conducting Phase IIA Clinical Trial for ASC10 to Treat Respiratory Syncytial Virus Infection

Ascletis Announces IND Approval of Oral Viral Polymerase Inhibitor ASC10 for Monkeypox Indication by China Nmpa

Ascletis Pharma Inc. Doses 4 Healthy Subjects of the First Cohort in Multiple-Dose Escalation Phase I Clinical Trial of Oral 3CLpro Inhibitor ASC11 for COVID-19

Viking Therapeutics, Inc. Files Complaints Against Ascletis Pharma Inc

Ascletis Announces Positive Phase I Clinical Results of Oral Rdrp Inhibitor Asc10 for Covid-19

Ascletis Pharma Inc. Announces IND Approval of Oral 3CLpro Inhibitor ASC11 for COVID-19 by China NMPA

Ascletis Announces Completion of 180 Patient Enrollment for Phase II Clinical Trial of FASN Inhibitor Asc40 for Acne

Ascletis Pharma Inc. Announces IND Filing of Oral 3CLpro Inhibitor ASC11 for COVID-19 Accepted by China NMPA

Ascletis Announces IND Approval of Oral 3CLpro Inhibitor ASC11 for Covid-19 by U.S. FDA

Insufficient new directors

Ascletis Pharma Inc. Announces IND Approval of Oral PD-L1 Small Molecule Inhibitor ASC61 for Treatment of Advanced Solid Tumors by China NMPA

Ascletis Pharma Inc. Announces IND Approval of Viral Polymerase Inhibitor ASC10 for Monkeypox Indication by U.S. FDA

Ascletis Pharma Inc. Announces Poster Presentation of Phase I, Single-Dose Study of ASC43F for NASH at AASLD Annual Meeting 2022

Ascletis Announces U.S. IND Filing of Oral 3CLpro Inhibitor ASC11 for COVID-19

Ascletis Pharma Inc. Announces U.S. IND Filing of Oral Antiviral ASC10 for Monkeypox Indication

Ascletis Announces Dosing of 24 Healthy Subjects of the First 3 Cohorts in Multiple-Dose Escalation Phase I Clinical Trial of Oral RdRp Inhibitor ASC10 for COVID-19

Ascletis Pharma Inc. Announces Dosing of the First Patient in Phase Ii Clinical Trial of Thrß Agonist Asc41 for 52-Week Treatment of Liver Biopsy-Proven Nash

Ascletis Announces Dosing of the First Patient in the Phase IIb Expansion Cohort of ASC22 (Envafolimab) for Chronic Hepatitis B Functional Cure

Ascletis Pharma Inc. Announces Clinical Study of PD-L1 antibody ASC22

First half 2022 earnings released: CN¥0.081 loss per share (vs CN¥0.10 loss in 1H 2021)

Ascletis Pharma Inc. Announces Change of Company Secretary

Ascletis Announces IND Approval of Oral RdRp Inhibitor ASC10 for COVID-19 by China NMPA

Vascletis Pharma Inc. Announces First Subject Dosed in the U.S. Drug-Drug Interaction Study of FXR Agonist ASC42 for Treatment of Primary Biliary Cholangitis

Ascletis Announces First Patient Dosed in the U.S. Phase I Clinical Trial of Oral PD-L1 Small Molecule Inhibitor Prodrug ASC61 for Treatment of Advanced Solid Tumors

Ascletis Announces IND Filing of Oral RdRp Inhibitor ASC10 for COVID-19 Accepted by China NMPA

Ascletis Announces FDA Clearance of Oral RdRp Inhibitor ASC10 to Conduct a Randomized, Placebo Controlled Phase Ib Study in Mild-to-Moderate COVID-19 Patients

Ascletis Pharma Inc. to Report First Half, 2022 Results on Aug 22, 2022

Forecast to breakeven in 2023

Insufficient new directors

Ascletis Announces U.S. IND Filing of Oral RdRp Inhibitor Drug Candidate ASC10 for COVID-19

Ascletis Pharma Inc. Announces Shanghai Public Health Clinical Center Completed the First Patient Dosing in Clinical Study of PD-L1 Antibody ASC22 in Combination with Chidamide for Functional Cure of HIV Infection

Ascletis Pharma Inc. Announces First Subject Dosed in the Phase II Clinical Trial of ASC22 (Envafolimab) for Immune Restoration/ Functional Cure of HIV-1 Infection

Ascletis Pharma Inc. Announces the Latest Phase Iib Clinical Trial Results of Subcutaneous Pd-L1 Antibody Asc22 (Envafolimab) in Patients with Chronic Hepatitis B (Chb) At an Oral Parallel Session of the International Liver Congress™ 2022

Ascletis Pharma Inc. Announces Oral Presentation on Updates from Phase IIb Clinical Trial of ASC22, a Subcutaneous PD-L1 Antibody for Functional Cure of Chronic Hepatitis B at EASL ILC 2022

Ascletis Pharma Inc. Appoints John P. Gargiulo as Chief Business Officer

Ascletis Pharma Inc., Annual General Meeting, Jun 16, 2022

Ascletis Pharma Inc. Announces Approval of Investigational New Drug Application

Insufficient new directors

Full year 2021 earnings released: CN¥0.18 loss per share (vs CN¥0.20 loss in FY 2020)

Ascletis Pharma Inc. Announces 3CLpro Inhibitor ASC11 Demonstrated Potential to be Effective Treatment for COVID-19

Ascletis Pharma Inc. Receives Approval for Investigational New Drug Application by China National Medical Products Administration

Ascletis Pharma Inc. Completes Patient Enrollment in Phase II Clinical Trial of ASC42 for Chronic Hepatitis B Indication

Insufficient new directors

Ascletis Pharma Inc. Announces the Latest Results of Preclinical Studies of Two Novel Anti-Cancer Drug Candidates,ASC61 and ASC60, to Be Presented At AACR Annual Meeting 2022

Ascletis Pharma Inc. to Report Fiscal Year 2021 Results on Mar 21, 2022

Ascletis Pharma Inc. Provides Earnings Guidance for the Year Ended December 31, 2021